S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
WARNING TO ALL U.S. INVESTORS (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
WARNING TO ALL U.S. INVESTORS (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
WARNING TO ALL U.S. INVESTORS (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
WARNING TO ALL U.S. INVESTORS (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
NASDAQ:SUPN

Supernus Pharmaceuticals (SUPN) Stock Forecast, Price & News

$33.62
+0.08 (+0.24%)
(As of 05/26/2023 ET)
Compare
Today's Range
$33.30
$33.76
50-Day Range
$33.54
$38.73
52-Week Range
$25.80
$42.09
Volume
179,681 shs
Average Volume
389,442 shs
Market Capitalization
$1.83 billion
P/E Ratio
37.78
Dividend Yield
N/A
Price Target
$46.00

Supernus Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
36.8% Upside
$46.00 Price Target
Short Interest
Bearish
9.13% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.35
Upright™ Environmental Score
News Sentiment
1.03mentions of Supernus Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$172,032 Sold Last Quarter
Proj. Earnings Growth
58.78%
From $1.31 to $2.08 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.61 out of 5 stars

Medical Sector

108th out of 1,018 stocks

Pharmaceutical Preparations Industry

40th out of 498 stocks


SUPN stock logo

About Supernus Pharmaceuticals (NASDAQ:SUPN) Stock

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.

Receive SUPN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Supernus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SUPN Stock News Headlines

"Chilling War Games Show US Forces Crushed" – FOX NEWS
=== BREAKING === "Chilling War Games Show US Forces Crushed" - FOX NEWS After losing to China in repeated war games, U.S. military to spend billions on new "living missile" for armed forces. Investors stand to reap 35,960% on shares of small defense contractor that makes powerful new weapon. Get the name of the stock here >>>
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser
Small cap wins $1.65 billion contract to make them. GlobeNewswire says this is a $51.1 Billion market by 2026. See why this stock could soar 2,476% >>>
Supernus Announces Repayment of Convertible Notes
Q4 2022 Supernus Pharmaceuticals Inc Earnings Call
Supernus Enters Into $150 Million Credit Facility
See More Headlines
Receive SUPN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Supernus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SUPN Company Calendar

Last Earnings
5/09/2023
Today
5/27/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:SUPN
CUSIP
86845910
Employees
575
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$46.00
High Stock Price Forecast
$46.00
Low Stock Price Forecast
$46.00
Forecasted Upside/Downside
+36.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$60.71 million
Pretax Margin
8.23%

Debt

Sales & Book Value

Annual Sales
$667.24 million
Cash Flow
$2.81 per share
Book Value
$16.74 per share

Miscellaneous

Free Float
50,123,000
Market Cap
$1.83 billion
Optionable
Optionable
Beta
1.04

Key Executives

  • Jack A. Khattar
    President, CEO, Secretary & Director
  • Timothy C. Dec
    Chief Financial Officer & Senior Vice President
  • Frank Mottola
    Senior VP-Quality, GMP Operations & IT
  • Padmanabh P. Bhatt
    Chief Scientific Officer & Senior Vice President
  • Jonathan Rubin
    Chief Medical Officer & Senior Vice President













SUPN Stock - Frequently Asked Questions

Should I buy or sell Supernus Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Supernus Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SUPN shares.
View SUPN analyst ratings
or view top-rated stocks.

What is Supernus Pharmaceuticals' stock price forecast for 2023?

1 analysts have issued 1 year target prices for Supernus Pharmaceuticals' shares. Their SUPN share price forecasts range from $46.00 to $46.00. On average, they predict the company's stock price to reach $46.00 in the next year. This suggests a possible upside of 36.8% from the stock's current price.
View analysts price targets for SUPN
or view top-rated stocks among Wall Street analysts.

How have SUPN shares performed in 2023?

Supernus Pharmaceuticals' stock was trading at $35.67 at the beginning of the year. Since then, SUPN stock has decreased by 5.7% and is now trading at $33.62.
View the best growth stocks for 2023 here
.

When is Supernus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our SUPN earnings forecast
.

How were Supernus Pharmaceuticals' earnings last quarter?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) released its quarterly earnings data on Tuesday, May, 9th. The specialty pharmaceutical company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.12 by $0.17. The specialty pharmaceutical company had revenue of $153.80 million for the quarter, compared to the consensus estimate of $139.02 million. Supernus Pharmaceuticals had a net margin of 7.79% and a trailing twelve-month return on equity of 5.96%. The firm's quarterly revenue was up .9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.43 earnings per share.

What guidance has Supernus Pharmaceuticals issued on next quarter's earnings?

Supernus Pharmaceuticals updated its FY 2023 earnings guidance on Tuesday, May, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $580.00 million-$620.00 million, compared to the consensus revenue estimate of $599.79 million.

What is Jack A. Khattar's approval rating as Supernus Pharmaceuticals' CEO?

20 employees have rated Supernus Pharmaceuticals Chief Executive Officer Jack A. Khattar on Glassdoor.com. Jack A. Khattar has an approval rating of 81% among the company's employees.

What other stocks do shareholders of Supernus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Supernus Pharmaceuticals investors own include NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), GW Pharmaceuticals (GWPH), Netflix (NFLX), Corcept Therapeutics (CORT) and Cara Therapeutics (CARA).

What is Supernus Pharmaceuticals' stock symbol?

Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."

Who are Supernus Pharmaceuticals' major shareholders?

Supernus Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (17.44%), Armistice Capital LLC (7.99%), Macquarie Group Ltd. (4.54%), Dimensional Fund Advisors LP (4.39%), Stephens Investment Management Group LLC (3.05%) and GW&K Investment Management LLC (2.60%). Insiders that own company stock include Frank Mottola, Frederick M Hudson, Gregory S Patrick, Jack A Khattar, Padmanabh P Bhatt, Stefan KF Schwabe and Tami Tillotson Martin.
View institutional ownership trends
.

How do I buy shares of Supernus Pharmaceuticals?

Shares of SUPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Supernus Pharmaceuticals' stock price today?

One share of SUPN stock can currently be purchased for approximately $33.62.

How much money does Supernus Pharmaceuticals make?

Supernus Pharmaceuticals (NASDAQ:SUPN) has a market capitalization of $1.83 billion and generates $667.24 million in revenue each year. The specialty pharmaceutical company earns $60.71 million in net income (profit) each year or $0.89 on an earnings per share basis.

How many employees does Supernus Pharmaceuticals have?

The company employs 575 workers across the globe.

How can I contact Supernus Pharmaceuticals?

Supernus Pharmaceuticals' mailing address is 1550 E GUDE DR, ROCKVILLE MD, 20850. The official website for the company is www.supernus.com. The specialty pharmaceutical company can be reached via phone at (301) 838-2500, via email at gpatrick@supernus.com, or via fax at 301-838-2501.

This page (NASDAQ:SUPN) was last updated on 5/27/2023 by MarketBeat.com Staff

My Account -